Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ford

Showing results (491-500 of 568) with videos related to

Pageof 57
Sort By:
Journal of Animal Physiology and Animal Nutrition|October 29, 2021
Effect of poultry offal silage with or without betaine supplementation on growth performance, intestinal morphometry, spleen histomorphology of Nile tilapia (Oreochromis niloticus) fingerlingsAlaa Eldin Eissa, Mohamed S Yusuf, Nehal A Younis, et al.
Journal of Medical Economics|May 5, 2022
Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trialsJoshua Tobin, Janet H Ford, Antje Tockhorn-Heidenreich, et al.
Headache|November 29, 2020
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With MigraineJanet H Ford, Tobias Kurth, Amaal J Starling, et al.
Nucleosides & Nucleotides|August 5, 1999
Conformationally restricted nucleosides. The reaction of adenosine deaminase with substrates built on a bicyclo[3.1.0]hexane templateV E Marquez, P Russ, R Alonso, et al.
Health Physics|January 1, 1989
An assessment of soil-to-plant concentration ratios for some natural analogues of the transuranic elementsP Linsalata, R S Morse, H Ford, et al.
Journal of Medical Economics|August 16, 2022
Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN)Joshua A Tobin, Shivang Joshi, Janet H Ford, et al.
Journal of Studies on Alcohol and Drugs|September 21, 2017
Promoting Adoption of Medication for Opioid and Alcohol Use Disorders Through System ChangeJames H Ford, Amanda J Abraham, Nicoleta Lupulescu-Mann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1995
The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapyM J Boyle, M Connors, M E Flanigan, et al.
European Journal of Neurology|November 7, 2019
Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trialsD D Ruff, J H Ford, A Tockhorn-Heidenreich, et al.
European Journal of Neurology|February 14, 2020
Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'P J Goadsby, G M Terwindt, D D Ruff, et al.
Pageof 57

Showing results (491-500 of 568) with videos related to

Sort By:
Pageof 57
Journal of Animal Physiology and Animal Nutrition|October 29, 2021
Effect of poultry offal silage with or without betaine supplementation on growth performance, intestinal morphometry, spleen histomorphology of Nile tilapia (Oreochromis niloticus) fingerlingsAlaa Eldin Eissa, Mohamed S Yusuf, Nehal A Younis, et al.
Journal of Medical Economics|May 5, 2022
Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trialsJoshua Tobin, Janet H Ford, Antje Tockhorn-Heidenreich, et al.
Headache|November 29, 2020
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With MigraineJanet H Ford, Tobias Kurth, Amaal J Starling, et al.
Nucleosides & Nucleotides|August 5, 1999
Conformationally restricted nucleosides. The reaction of adenosine deaminase with substrates built on a bicyclo[3.1.0]hexane templateV E Marquez, P Russ, R Alonso, et al.
Health Physics|January 1, 1989
An assessment of soil-to-plant concentration ratios for some natural analogues of the transuranic elementsP Linsalata, R S Morse, H Ford, et al.
Journal of Medical Economics|August 16, 2022
Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN)Joshua A Tobin, Shivang Joshi, Janet H Ford, et al.
Journal of Studies on Alcohol and Drugs|September 21, 2017
Promoting Adoption of Medication for Opioid and Alcohol Use Disorders Through System ChangeJames H Ford, Amanda J Abraham, Nicoleta Lupulescu-Mann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1995
The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapyM J Boyle, M Connors, M E Flanigan, et al.
European Journal of Neurology|November 7, 2019
Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trialsD D Ruff, J H Ford, A Tockhorn-Heidenreich, et al.
European Journal of Neurology|February 14, 2020
Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'P J Goadsby, G M Terwindt, D D Ruff, et al.
Pageof 57